Obesity


Healthcare Survey

Low awareness of GLP-1s globally, but high in the most advanced economies

Despite media discussions around the drugs, only around a third across 30 countries have heard about the drugs, with a lot of the discourse taking place via social media according to the Ipsos Health Service Report.
Healthcare Publication

Healthcare vs Evolution: Can GLP-1s Rewrite Our Evolutionary Story?

GLP-1s are more than just weight loss drugs. They're a chance to rewrite our evolutionary story, to take control of our biology in a way never before possible.
Ipsos Update Publication

Ipsos Update – December 2024

Security, Inflation, Perils of Perception … Ipsos Update explores the latest and research & thinking on key topics from Ipsos teams around the world.
Healthcare Publication

GLP–1s: A Healthcare Revolution?

One of this century’s biggest game-changers will likely be a novel drug class that’s showing unprecedented success, or the promise of it, in treating some of the world’s most prevalent conditions.

Half of Americans would be interested in a weight loss medication

More than half of Americans would be interested in taking a new 'safe and effective' weight loss treatment, according to new data from the Ipsos Consumer Tracker
Obesity Survey

Though 85% of Americans Say They Have the Knowledge Needed to Eat Right, Majority Obtain a Failing Grade on Fat IQ Test

Most Are Not Content with Their Current Weight, With Two Thirds of Americans’ BMI Scores in the Overweight/Obese Range